论文部分内容阅读
目的观察半胱氨酸白三烯受体拮抗剂——普仑司特(pranlukast)对变应性鼻炎动物模型鼻黏膜组织重塑的影响。方法Hartley豚鼠14只,随机分为3组,即阴性对照组、卵清蛋白(ovalbumin,OVA)组和OVA+普仑司特组。OVA组:致敏的豚鼠经鼻长期OVA激发共12周;OVA +普仑司特组:致敏的豚鼠经鼻抗原激发1周后,抗原激发的同时给予普仑司特腹腔注射11周;阴性对照组仅给予生理盐水腹腔注射。标本石蜡包埋,做苏木素-伊红、阿辛蓝-过碘酸-希夫(alcian blue- periodic acid-Schiff,AB-PAS)和Masson三色胶原(Masson Trichrome,MT)染色,计数鼻中隔黏膜中的嗜酸粒细胞、上皮杯状细胞数量,半定量测量上皮细胞损伤及鼻中隔黏膜和鼻甲基底膜区及上皮下胶原含量,测定数值以x±s表示。结果与阴性对照相比,OVA组发生鼻中隔黏膜嗜酸粒细胞浸润[400倍镜下细胞数,(106．90±13．66)个／镜下]、上皮细胞损伤(完整上皮占47．25％±7．67％)、杯状细胞化生[每毫米基底膜对应上皮细胞中杯状细胞数,(22．05±5．81)个／mm]和鼻中隔黏膜及鼻甲内细胞外基质沉积明显增多;OVA+普仑司特组未见明显鼻中隔黏膜嗜酸粒细胞浸润[(8．95±2．32)个／镜下]、上皮细胞损伤(完整上皮占83．15％±8．05％),杯状细胞化生[(5．73±1．07)个／mm]以及鼻中隔黏膜及鼻甲内细胞外基质沉积。OVA+普仑司特组与阴性对照组差异无统计学意义。结论普仑司特能够阻止长期抗原激发导致的鼻黏膜组织重塑的发生,早期应用普仑司特对变应性鼻炎的治疗具有一定意义。
Objective To investigate the effect of cysteinyl leukotriene receptor antagonist - pranlukast on nasal mucosa remodeling in an animal model of allergic rhinitis. Methods 14 Hartley guinea pigs were randomly divided into 3 groups: negative control group, ovalbumin (OVA) group and OVA + pranlukast group. OVA group: sensitized guinea pigs were challenged by long-term nasal OVA for 12 weeks; OVA + pranlukast group: sensitized guinea pigs were intraperitoneally injected with pranlukast for 11 weeks after being challenged by nasal antigen for 1 week; Negative control group was given intraperitoneal injection of saline only. The specimens were paraffin-embedded and stained with hematoxylin-eosin, alcian blue-periodic acid-Schiff (AB-PAS) and Masson Trichrome (MT) In the number of eosinophils, epithelial goblet cells, semi-quantitative measurement of epithelial cell damage and nasal septum mucosa and nasal basement membrane area and the amount of collagen under the skin, measured values to x ± s said. Results Compared with the negative control group, nasal septum mucosal eosinophil infiltration was observed in OVA group [(106.90 ± 13.66) cells / (106.90 ± 13.66) / epithelial cells, epithelial cell injury (47.25% % ± 7.67%), goblet cell metaplasia [(22.05 ± 5.81) / mm in epithelial cells per mm basement membrane and extracellular matrix deposition in nasal septum and turbinate) (8.95 ± 2.32) per microscopic in epithelial cells in OVA + pranlukast group, epithelial cell injury (83.15% ± 8.05 in complete epithelium, %), Goblet cell metaplasia [(5.73 ± 1.07) / mm], and extracellular matrix deposition in nasal septum mucosa and turbinates. There was no significant difference between OVA + pranlukast group and negative control group. Conclusion Pranlukast can prevent nasal mucosa remodeling caused by long-term antigen challenge. Early use of pranlukast has some significance for the treatment of allergic rhinitis.